Skip to main content
Lance Leopold, MD, Oncology, Dresher, PA

Lance Leopold MD

Oncology•Dresher, PA

Physician

Join to View Full Profile

  • 1441 Catlin WayDresher, PA 19025

  • Phone+1 610-203-9328

  • Fax+1 866-305-6063

Join Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 1 invite waiting!
  • Read the latest clinical news, personalized to your specialty.
Join DoximityAlready have an account?

Summary

  • Dr. Lance Leopold, MD is an oncologist in Dresher, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania.

Education & Training

  • Temple University Hospital-Fox Chase Cancer Center
    Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 1990 - 1993
  • Temple University Hospital
    Temple University HospitalResidency, Internal Medicine, 1987 - 1990
  • Lewis Katz School of Medicine at Temple University
    Lewis Katz School of Medicine at Temple UniversityClass of 1987

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1989 - 2026

Publications & Presentations

PubMed

Press Mentions

  • Incyte and Mirati Therapeutics Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors
    Incyte and Mirati Therapeutics Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid TumorsNovember 7th, 2022
  • Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
    Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)June 24th, 2021
  • Incyte Announces the Validation by the European Medicines Agency of Its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)
    Incyte Announces the Validation by the European Medicines Agency of Its Marketing Authorization Application for Retifanlimab as a Treatment for Patients with Squamous Cell Anal Carcinoma (SCAC)February 26th, 2021

Dr. Lance Leopold, Dr. Lance Leopold, MD, Dr. L Leopold